Charles Schwab Investment Management Inc. Has $14.71 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Charles Schwab Investment Management Inc. decreased its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 32.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 651,582 shares of the company's stock after selling 313,100 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.54% of 10x Genomics worth $14,713,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in TXG. ARK Investment Management LLC lifted its stake in shares of 10x Genomics by 15.4% in the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company's stock worth $242,743,000 after acquiring an additional 1,436,582 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in 10x Genomics by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company's stock valued at $143,907,000 after acquiring an additional 230,145 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of 10x Genomics by 69.6% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company's stock worth $119,483,000 after purchasing an additional 2,521,289 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in shares of 10x Genomics during the second quarter worth about $11,612,000. Finally, Squarepoint Ops LLC grew its stake in 10x Genomics by 1.1% in the second quarter. Squarepoint Ops LLC now owns 515,883 shares of the company's stock worth $10,034,000 after purchasing an additional 5,720 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

10x Genomics Stock Performance

TXG traded up $0.64 during trading on Friday, reaching $15.87. The stock had a trading volume of 1,301,393 shares, compared to its average volume of 2,022,598. The stock has a 50 day moving average of $16.25 and a two-hundred day moving average of $19.23. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $57.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business had revenue of $151.65 million during the quarter, compared to analyst estimates of $158.84 million. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The company's revenue was down 1.3% on a year-over-year basis. Research analysts predict that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TXG. Leerink Partners began coverage on 10x Genomics in a report on Tuesday, September 3rd. They set an "outperform" rating and a $35.00 target price on the stock. Barclays decreased their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a research report on Wednesday, October 30th. Finally, Citigroup dropped their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.19.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.